BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS
Clinical trials for BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS explained in plain language.
Never miss a new study
Get alerted when new BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS trials appear
Sign up with your email to follow new studies for BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill trial targets early mesothelioma in High-Risk gene carriers
Disease control TerminatedThis study tests an oral drug (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will be enrolled, and the study is currently on hold.
Matched conditions: BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 08:00 UTC
-
Promising mesothelioma drug study halted before it began
Disease control TerminatedThis study aimed to test the drug alrizomadlin (APG-115) in people with a genetic condition called BAP1 cancer syndrome who had early-stage mesothelioma. The goal was to see if the drug could stabilize or improve the disease. However, the study was withdrawn before any participan…
Matched conditions: BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC